4-(4-amino-2-fluorophenoxy)-N-(4-methoxybenzyl)pyrimidin-2-amine | 868733-46-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(4-amino-2-fluorophenoxy)-N-(4-methoxybenzyl)pyrimidin-2-amine
• 英文别名: N-(4-methoxybenzyl)-4-(4-amino-2-fluorophenoxy)pyrimidin-2-amine；4-(4-amino-2-fluorophenoxy)-N-[(4-methoxyphenyl)methyl]pyrimidin-2-amine
• CAS: 868733-46-4
• 化学式: C₁₈H₁₇FN₄O₂
• 分子量: 340.357
• InChiKey: MDLZJEVVUJVUIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  82.3
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-(4-amino-2-fluorophenoxy)-N-(4-methoxybenzyl)pyrimidin-2-amine 、 1-(4-氟苯基氨基甲酰基)环丙烷羧酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 36.0h， 生成 N-(4-(2-aminopyrimidin-4-yloxy)-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
  参考文献：
  名称：

  合成和评估一系列作为II型c-Met抑制剂的吡啶和嘧啶衍生物。

  摘要：

  在这项研究中，设计，合成和生物学评估了一系列新颖的吡啶和含嘧啶的衍生物的c-Met抑制活性。在生物学评估中，一半的目标化合物表现出中等至有效的c-Met抑制活性。其中，值得注意的是，化合物13d不仅显示出最强的c-Met抑制能力，而且显示出出色的抗增殖活性（针对EBC-1细胞系的IC50 = 127nM）以及可接受的激酶选择性谱。此外，蛋白质印迹分析表明13d以剂量依赖的方式抑制了EBC-1细胞中的c-Met磷酸化，并在0.1mM时被完全消除。所有这些实验结果表明，13d可以作为抗癌药物开发的有前途的先导化合物。

  DOI：

  10.1016/j.bmc.2017.04.003
• 作为产物：
  描述：

  2-氟-4-硝基苯酚 在 potassium carbonate 、 氯化铵 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 4-(4-amino-2-fluorophenoxy)-N-(4-methoxybenzyl)pyrimidin-2-amine
  参考文献：
  名称：

  Discovery of Novel c-Met Inhibitors Bearing a 3-Carboxyl Piperidin-2-one Scaffold

  摘要：

  一系列包含新型3-羧基哌啶-2-酮骨架的化合物基于引导结构BMS-777607进行设计、合成并评估其对c-Met激酶的抑制作用及对MKN45癌细胞系的细胞毒性。结果表明，五种化合物对c-Met展现出显著的抑制效果，IC50值为8.6−81 nM，而四种化合物对MKN45细胞增殖表现出强劲的抑制活性，IC50在0.57−16 μM之间。

  DOI：

  10.3390/molecules19022655

文献信息

• Monocyclic heterocycles as kinase inhibitors
  申请人：Borzilleri M. Robert

  公开号：US20050245530A1

  公开（公告）日：2005-11-03

  The present invention is directed to compounds having the formula and methods for using them for the treatment of cancer.

  本发明涉及具有以下公式化合物的用途以及使用它们治疗癌症的方法。
• Discovery of Novel c-Met Inhibitors Bearing a 3-Carboxyl Piperidin-2-one Scaffold
  作者：Wei Zhang、Jing Ai、Dakuo Shi、Xia Peng、Yinchun Ji、Jian Liu、Meiyu Geng、Yingxia Li

  DOI：10.3390/molecules19022655

  日期：——

  A series of compounds containing a novel 3-carboxypiperidin-2-one scaffold based on the lead structure BMS-777607 were designed, synthesized and evaluated for their c-Met kinase inhibition and cytotoxicity against MKN45 cancer cell lines. The results indicated that five compounds exhibited significant inhibitory effect on c-Met with IC50 values of 8.6−81 nM and four compounds showed potent inhibitory activity against MKN45 cell proliferation, with IC50s ranging from 0.57−16 μM.

  一系列包含新型3-羧基哌啶-2-酮骨架的化合物基于引导结构BMS-777607进行设计、合成并评估其对c-Met激酶的抑制作用及对MKN45癌细胞系的细胞毒性。结果表明，五种化合物对c-Met展现出显著的抑制效果，IC50值为8.6−81 nM，而四种化合物对MKN45细胞增殖表现出强劲的抑制活性，IC50在0.57−16 μM之间。
• MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS
  申请人：Borzilleri Robert M.

  公开号：US20090054436A1

  公开（公告）日：2009-02-26

  The present invention is directed to compounds having the formula and methods for using them for the treatment of cancer.

  本发明涉及具有以下结构式的化合物及其用于癌症治疗的方法。
• New aminopyrimidine derivatives as inhibitors of the TAM family
  作者：Ténin Traoré、Andrea Cavagnino、Nicolas Saettel、François Radvanyi、Sandrine Piguel、Isabelle Bernard-Pierrot、Véronique Stoven、Michel Legraverend

  DOI：10.1016/j.ejmech.2013.10.037

  日期：2013.12

  In this study, we describe the synthesis of new pyrimidine analogs of BMS-777607, a potent and selective inhibitor of Met kinase. Inhibition of Met and Axl remained high whereas inhibition of Tyro3 and Mer decreased to some extend. The preferential moderate inhibition of the non-phosphorylated form of Abl1 of some derivatives suggests that they behave as type II inhibitors. This hypothesis was confirmed by docking studies into the structure of Met (3F82) and in a Tyro3 model where key interactions with the hinge region, the DFG-out motif and the allosteric pocket explain this inhibition. (C) 2013 Elsevier Masson SAS. All rights reserved.
• Discovery of novel type II c-Met inhibitors based on BMS-777607
  作者：Wei Zhang、Jing Ai、Dakuo Shi、Xia Peng、Yinchun Ji、Jian Liu、Meiyu Geng、Yingxia Li

  DOI：10.1016/j.ejmech.2014.04.056

  日期：2014.6

  Twenty-two new analogs based on the structure of BMS-777607 were designed, synthesized, and evaluated to determine their biological activities. Compounds bearing a cyclic sulfonamide or α-chloropiperidone scaffold exhibited good activity, which may provide a new basis for further structural optimization. Quinoline-containing analogs exhibited better results than did their counterparts with an aminopyrimidine, aminopyridine, or pyrrolopyridine unit. Two analogs, 22d and 22e, stood out as the most potent c-Met inhibitors with IC50s of 0.9 and 1.7 nM, respectively. These two compounds were more potent than BMS-777607 in enzymatic inhibition and cell proliferation studies.